drugset / Trial / NCT06988553

A Phase Ib Study of AZD5004 in Chinese Participants With Overweight/Obesity With or Without Type 2 Diabetes Mellitus

NCT06988553

Phase 1 Completed 45 enrolled Eccogene
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability, and PK of AZD5004 compared with placebo in Chinese participants with overweight/obesity with or without T2DM.

Timeline

Start
2025-06-17
Primary completion
2025-11-28
Completion
2025-11-28

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD5004 Unknown Oral